Opportunities & Solicitations
How Does This Work?
JPM-MCS offers funding opportunities to MCDC members through solicitations called Requests for Prototype Proposals (RPPs). The RPPs offer MCDC members the opportunity to propose prototype technologies to the technology requirements in each solicitation’s objective or sub-objective area. Active and Closed solicitations are listed below.
Only MCDC Members in good standing can submit whitepapers and proposals in response to solicitations. Please log-in to the MCDC Members Only Site to view complete solicitation information. If you do not have a username and password, please click here to request access.
If you are not a MCDC member and wish to become one, please click here for instructions.
INTENT TO ANNOUNCE
Request for Prototype Proposal (RPP) MCDC-RPP-17-03 was released June 16, 2017 and solicited 1) a full proposal only for Sub-Objective area 17-06, 2) a whitepaper followed by full proposal for Sub-Objective area 17-07, and 3) a whitepaper followed by full proposal for Sub-Objective area 17-08.
MCDC-RPP-17-03 is for the Objective Areas “Prevention” and “Detection” and includes the following three Sub-Objective Areas:
PRE-17-06: Execution of Phase 1 Clinical Study for Venezuelan Equine Encephalitis (VEE) Monovalent Virus Replicon Particle (VRP) vaccine
DET-17-07: Man-Portable Diagnostics System (MPDS) – Expanded Scope
DET-17-08: Chemical Exposure In Vitro Diagnostics (IVD) (ChemDx)
Request for Prototype Proposal (RPP) MCDC-RPP-17-01 was released January 17, 2017 and solicited 1) a full proposal only for Sub-Objective area 17-01 and 2) a whitepaper followed by full proposal for Sub-Objective area 17-02.
Active Requests For Information
MCDC-RFI for MCM Platforms
A Request for Information (RFI) MCDC-RFI-Platform Technologies was released June 2, 2017 by the Medical Countermeasure (MCM) Platforms Team at the Joint Program Executive Office for Chemical and Biological Defense (Medical Countermeasures Systems) and the Joint Science and Technology Office (Vaccine and Therapeutic Division).
The RFI seeks information on the capabilities and willingness of private entities (non-profit and commercial) in platform technologies that can counter a variety of chemical and biological threat agents by standardizing product discovery, design, manufacturing, and/or testing to accelerate MCM delivery to the Warfighter. The RFI can be found here
CLOSED SOLICITATIONS AND REQUESTS FOR INFORMATION
Request for Prototype Proposal (RPP) MCDC-RPP-17-02 was released February 13, 2017 and solicited full proposals
17-03: Development of Marburgvirus (MARV) Vaccine Prototype against aerosolized MARV
17-04: Development of Multi-Target Single-Vector Vaccine Prototype against aerosolized Venezuelan Equine Encephalitis Virus (VEEV)
17-05: Man-Portable Diagnostics System (MPDS)
MCDC-RPP-17-0117-02: Development of Efficacious Antiviral Countermeasures
MCDC-RFI for DBPAO
Two (2) Request for Information (RFI) MCDC-RFI for DBPAO were released January 17, 2017 on behalf of the Defense Biological Product Assurance Office (DBPAO), formally the Critical Reagents Program (CRP).
The first RFI seeks information regarding qualifications on capability to produce, manufacture or provide inactive viral and bacterial antigens. The RFI can be found here
The second RFI seeks information on third-party conformance testing. The RFI can be found here
Request for Prototype Proposal (RPP) MCDC-RPP-16-02 was released July 15, 2016 and solicited whitepapers followed by full proposals
MCDC-RPP-16-02 is for the Objective Areas “Treatment” (TRE) and “Prevention” (PRE) and includes the following four Sub-Objective Areas:
16-03: Development of a Dual Drug Delivery Device (D4) Autoinjector
16-04: Lyophilized Formulation and Final Product Manufacturing Process for Western, Eastern, and Venezuelan equine encephalitis (WEVEE) Vaccine
16-05: Venezuelan equine encephalitis (VEE) Monovalent VLP Phase I Clinical Study
16-06: Eastern Equine Encephalitis Virus Advanced Technology Demonstration (EEEV ATD)
Request for Prototype Proposal (RPP) MCDC-RPP-16-01 was released June 22, 2016 and solicited full proposals (no whitepapers for this RPP).
MCDC-RPP-16-01 is for the Objective Area “Prevention” and includes the following two Sub-Objective Areas:
16-01: Fill/Finish of Venezuelan Equine Encephalitis (VEE) virus like particle (VLP) Bulk Drug Product
16-02: Development of Monoclonal Antibody Medical Countermeasures against Aerozolized Botulinum Toxin Serotypes A and B